These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38584553)

  • 1. Celastrol Elicits Antitumor Effects through Inducing Immunogenic Cell Death and Downregulating PD-L1 in ccRCC.
    Li HF; Zhu N; Wu JJ; Shi YN; Gu J; Qin L
    Curr Pharm Des; 2024; 30(16):1265-1278. PubMed ID: 38584553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
    Hirayama Y; Gi M; Yamano S; Tachibana H; Okuno T; Tamada S; Nakatani T; Wanibuchi H
    Cancer Sci; 2016 Dec; 107(12):1736-1744. PubMed ID: 27712020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celastrol mediates CAV1 to attenuate pro-tumorigenic effects of senescent cells.
    Zhang S; Zhu N; Shi YN; Zeng Q; Zhang CJ; Li HF; Qin L
    Phytomedicine; 2024 Jul; 129():155614. PubMed ID: 38692078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma.
    Zhang CJ; Zhu N; Long J; Wu HT; Wang YX; Liu BY; Liao DF; Qin L
    Acta Pharmacol Sin; 2021 Sep; 42(9):1472-1485. PubMed ID: 33303989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death.
    Duan XC; Peng LY; Yao X; Xu MQ; Li H; Zhang SQ; Li ZY; Wang JR; Feng ZH; Wang GX; Liao A; Chen Y; Zhang X
    Drug Deliv; 2021 Dec; 28(1):800-813. PubMed ID: 33866918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.
    Guo X; Li R; Bai Q; Jiang S; Wang H
    J Cell Mol Med; 2020 Dec; 24(24):14441-14452. PubMed ID: 33145941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YTHDF3 phase separation regulates HSPA13-dependent clear cell renal cell carcinoma development and immune evasion.
    Dai C; Cao J; Tang Y; Jiang Y; Luo C; Zheng J
    Cancer Sci; 2024 Aug; 115(8):2588-2601. PubMed ID: 38811341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
    McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
    Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
    Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
    Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis.
    Lee JH; Kim YJ; Ryu HW; Shin SW; Kim EJ; Shin SH; Park JY; Kim SY; Hwang CS; Na JY; Shin DH; Kim JY; Lee HJ
    Diagn Pathol; 2023 Mar; 18(1):36. PubMed ID: 36894965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
    Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy.
    Qiu N; Liu Y; Liu Q; Chen Y; Shen L; Hu M; Zhou X; Shen Y; Gao J; Huang L
    Biomaterials; 2021 Feb; 269():120604. PubMed ID: 33383300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
    Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
    Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kondo T; Shinohara N; Nonomura N; Ozono S; Eto M; Tatsugami K; Takayama T; Matsuyama H; Kishida T; Oya M;
    Cancer Sci; 2019 Jun; 110(6):1820-1828. PubMed ID: 30972888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
    Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
    Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
    Hara T; Miyake H; Hinata N; Fujisawa M
    Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.